Biofrontera AG reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was EUR 3.52 million compared to EUR 7.02 million a year ago. Net loss was EUR 0.931 million compared to EUR 3.14 million a year ago. Diluted loss per share from continuing operations was EUR 0.15.
For the nine months, sales was EUR 10.72 million compared to EUR 24.8 million a year ago. Net loss was EUR 6.27 million compared to EUR 6.29 million a year ago. Diluted loss per share from continuing operations was EUR 1.03 compared to EUR 2.1 a year ago.